In early trading on the 5th, D&D Pharmatech(347850) is plunging 17%. Selling is intensifying on news that Pfizer halted the trial of "MET-224o," which uses D&D Pharmatech's oral peptide platform technology "Orallink."
As of 9:24 a.m. that day, D&D Pharmatech was trading on the KOSDAQ market at 53,700 won, down 11,100 won (17.13%) from the previous trading day.
A media outlet reported that day that, after confirming the 2026 second-quarter earnings announcement, Pfizer halted the clinical trial of "MET-224o."
D&D Pharmatech transferred six oral anti-obesity drug candidates to Metsera, a U.S. biotech, in 2023–2024 for $803.5 million (about 1.12 trillion won). After Metsera was acquired by Pfizer last year, D&D Pharmatech's corporate value also climbed.
Pfizer had been seeking to enter the obesity drug market through MET-224o. MET-224o is the lead item among the substances D&D Pharmatech transferred to Metsera.
However, Pfizer said it will continue GLP-1 compound discovery. Some analysts also say the latest trial halt does not mean the D&D Pharmatech–Pfizer partnership has ended.